Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Hemogenyx Pharmaceuticals Fundamentals

Company Name Hemogenyx Pharmceuticals Last Updated 19 Oct 2020
Industry Health Care Sector Biotechnology
Shares in Issue (m) 433.64 Market Cap (£m) 39.90
PE Ratio -23.00 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -0.40 EPS Growth (%) 2.44
PEG -9.43 DPS Growth (%) n/a
Debt Ratio 140.21 Debt Equity Ratio 0.87
Net Gearing 85.71 Gross Gearing 133.24
Asset Equity Ratio -3.01 Cash Equity Ratio -142.98
Quick Ratio 3.05 Current Ratio 3.05
Price To Book Value -114.00 ROCE -171.26

Hemogenyx Pharmaceuticals Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Hemogenyx Pharmaceuticals Company Financials

Assets (£m) 2019 2018 2017
Tangible Assets 0 0 0
Intangible Assets 0 0 0
Investments 0 0 0
Total Fixed Assets 1 0 0
Stocks 0 0 0
Debtors 0 0 0
Cash & Equivalents 1 2 2
Other Assets 0 0 0
Total Assets 1 2 2
Liabilities (£m) 2019 2018 2017
Creditors within 1 year 0 0 0
Creditors after 1 year 1 1 0
Other Liabilities 0 0 0
Total Liabilities 1 1 0
Net assets -0 1 2
Equity (£m) 2019 2018 2017
Called up share capital 4 4 4
Share Premium 8 7 7
Profit / Loss -1 -2 -2
Other Equity -6 -6 -6
Preference & Minorities 0 0 0
Total Capital Employed -0 1 2
Ratios 2019 2018 2017
Debt Ratio 140.21 55.02 0.00
Debt-to-Equity 0.87 0.88 0.00
Net Gearing 85.71 -18.30 -67.32
Gross Gearing 133.24 58.30 11.02
Assets / Equity -3.01 2.40 1.12
Cash / Equity -142.98 183.73 88.04
EPS -0.40 -0.41 -1.00
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -1 -1 -0
Cashflow before financing -1 -1 1
Increase in Cash -1 -0 2
Income (£m) 2019 2018 2017
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -2 -2 -1
Pre-Tax profit -1 -2 -2
Profit / Loss for the year 4 4 4

Hemogenyx Pharmaceuticals Company Background

Sector Biotechnology
Activities Hemogenyx Pharmaceuticals plc (formerly Silver Falcon plc) with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liege. Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
Latest Interim Date 30 Sep 2020
Latest Fiscal Year End Date 30 Apr 2020

Hemogenyx Pharmaceuticals Directors

Appointed Director Position
2017-10-04 Dr Vladislav Sandler Chief Executive Officer
2018-04-09 Sir Marc Feldmann Executive Chairman
2017-10-04 Alexis Sandler Non-Executive Director
2015-07-29 Peter Redmond Non-Executive Director

Hemogenyx Pharmaceuticals Contact Details

Company Name Hemogenyx Pharmceuticals
Company Address 5 Fleet Place, London, EC4M 7RD.
Company Telephone n/a
Company Website http://www.hemogenyx.com/

Hemogenyx Pharmaceuticals Advisors

Auditor Name Littlejohn
Auditor Address 1 Westferry Circus, Canary Wharf, London E14 4HD.
Auditor Website http://www.littlejohnfrazer.com/
Auditor Telephone +44 (0)20 7516 2200
Registrar Name Computershare Investor Service
Registrar Address The Pavillions, Bridgwater Road, Bristol BS99 1XZ.
Registrar Website http://www-uk.computershare.com/
Registrar Telephone 0870 702 0010
Broker Name Optiva Securities
Broker Address 2 Mill Street, London W1S 2AT.
Broker Website http://www.optivasecurities.com/
Broker Telephone +44 (0)20 3137 1902
Adviser Name Peterhouse Corporate Finance
Adviser Address 31 Lombard Street, London EC3V 9BQ.
Adviser Website http://www.pcorpfin.com/
Adviser Telephone +44 (0)207 469 0930
Solicitor Name Charles Russell LLP
Solicitor Address 5 Fleet Place, London EC4M 7RD.
Solicitor Website http://www.cr-law.co.uk/
Solicitor Telephone +44 (0)20 7203 5000
Stockbroker Name Shard Capital Partners
Stockbroker Address 23rd Floor, 20 Fenchurch Street, London EC3M 3BY.
Stockbroker Website http://www.shardcapital.com/
Stockbroker Telephone +44 (0)207 186 9900